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IMMUNOTHERAPYI
t has long been recognized that the immune
system and malignant cells often coexist in a
dynamic equilibrium, and the complex interac-
tion between growing tumors and the immune
system may determine the course of disease.1–3
Tumors must develop the ability to evade the
immune system in order to proliferate and metasta-
size. The theory of immune surveillance suggests
that the immune system is proactively able to
eliminate abnormal cells and prevent cancer forma-
tion in the body. Studies have shown that patients
with compromised or suppressed immune function- see front matter
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Open access under CC BY-NC-ND license.are at increased risk of developing cancer.4–10 Addi-
tionally, although controversial, use of immunosup-
pressive agents has been associated with an
increased incidence of certain cancers.11 Clearly
the adaptive immune response is able to control
the growth of some tumors, as evidenced by the
observation that the presence of tumor-infiltrating
lymphocytes (TILs) often is associated with
improved overall survival (OS).12–14 However, the
immune system is rendered ineffective as tumors
progress. The dynamic process of cancer immunoe-
diting can be conceptualized by a seesaw that
balances immune protection with immune eva-
sion.15 Cancer immunoediting involves three stages:
elimination, equilibrium, and escape. In the elimina-
tion stage, cancer cells are identified and effectively
destroyed by the immune system. In the equilibrium
stage, the immune system is unable to completely
eliminate all cancer cells but is able to control or
prevent further outgrowth. The conceptual seesaw
is, therefore, balanced in the equilibrium stage. In
the escape stage, the immune system is unable to
eliminate and control the outgrowth of the tumor
because the cancer cells have evolved under the
selective pressure of the immune system, and those
cells that have acquired the ability to suppress or
evade the immune response continue to proliferate
and spread.
The goal of cancer immunotherapy is to boost or
restore the ability of the immune system to detectS3-S13 S3
M.L. DisisS4and destroy cancer cells by overcoming the mecha-
nisms by which tumors evade and suppress the
immune response,16 in essence to shift the equili-
brium back in favor of immune protection. The
hallmark of the adaptive immune response is specif-
icity and long-term memory, which, when present,
can result in durable responses. The traditional
approach to immunotherapy has been to increase
the frequency of tumor-specific T cells through
administration of tumor vaccines, cytokines such as
interleukin (IL)-2, and adoptive transfer of TILs. In
the last decade, efforts to improve presentation of
tumor antigens to the immune system have focused
on antigen-presenting cells (APCs) such as myeloid
dendritic cells (DCs). Another approach is to trigger
innate immune activation and inflammation in the
tumor microenvironment with agents such as type I
interferons (IFNs) and Toll-like receptor (TLR) ago-
nists. More recently, improved understanding of
immune regulatory mechanisms, such as cytotoxic
T-lymphocyte–associated antigen 4 (CTLA-4), pro-
grammed cell death 1 (PD-1), indoleamine-2,3-dioxy-
genase (IDO), regulatory T cells (Tregs), and
myeloid-derived suppressor cells (MDSCs), has led
to the development of agents that can modulate the
so-called “immune checkpoints” and new strategies
to deplete Tregs and MDSCs. Immune checkpoint
inhibitors have generated excitement because these
agents appear to overcome the very mechanisms
that tumors hijack in order to suppress the antitumor
immune response. Some of these modalities have
been tested clinically for decades, whereas others
are new, and even some of the older strategies
are being revisited with new twists based on our
current understanding of immuno-oncology. This
article reviews the mechanism of action of each of
these approaches.CYTOKINES
Cytokines have multiple and diverse biologic
activities.17 They can be grouped into different
functional classes including IFNs, ILs, chemokines,
mesenchymal growth factors, tumor necrosis factors
(TNFs), and adipokines. The majority of cytokines
serve as ligands for specific cell-surface receptors
and some act as transcription factors. The multiple
and varied activities of a single cytokine can be
attributed to differential expression of the cognate
receptor or the specific cell type in which the
cytokine is expressed.
Cytokines have been used as cancer immunother-
apy for decades, and they work by one of two
general mechanisms: either by exerting a direct
antitumor effect or by indirectly enhancing the
antitumor immune response.18 Numerous in vitro
and animal studies have shown that TNF-α and IL-6can directly affect tumor cell growth and survival.
Use of these particular direct-acting cytokines in
patients with cancer, however, has proven less
successful because of significant toxicity. For
instance, although TNF-α and IL-6 are able to sup-
press growth of some tumors, they actually promote
growth of others, and IL-6 can be immunosuppres-
sive. Therefore, the use of cytokines that have a
direct antitumor effect remains primarily an aca-
demic pursuit.
In contrast, cytokines that stimulate an antitumor
immune response through a variety of different
pathways have been widely used in clinical prac-
tice.18 For example, IL-2 and IFN-α promote growth
and activation of T cells and natural killer (NK) cells,
whereas granulocyte-macrophage colony-stimulating
factor (GM-CSF) acts on APCs to increase antigen
processing and presentation as well as production
of co-stimulatory cytokines. These cytokines are
well-established cancer immunotherapies. For exam-
ple, IL-2 is approved by the US Food and Drug
Administration (FDA) for the treatment of metastatic
melanoma and metastatic renal cell carcinoma, and
IFN-α is approved for the treatment of malignant
melanoma, as well as various types of leukemia and
lymphoma.19–22 Of note, GM-CSF is approved for its
hematopoietic reconstitution effect and not its anti-
tumor effect. Several other cytokines, such as IL-7,
IL-11, IL-12, IL-15, IL-21, IFN-β, and IFN-γ, also are
being evaluated as cancer immunotherapies.THERAPEUTIC CANCER VACCINES
The goal of therapeutic cancer vaccines is to
increase presentation of tumor-associated antigens
(TAAs) to the immune system and to increase
activation of tumor-specific T cells and B cells.23
Cancer vaccines can be classified into several major
categories: cell-based vaccines, protein/peptide vac-
cines, and genetic vaccines (Table 1).
Tumor cell vaccines can be either autologous
(derived from patient-specific tumor cells) or allo-
geneic (produced from established human tumor
cell lines).24 The advantage of cell-based vaccine
approaches lies in the potential to present the
entire spectrum of tumor-associated antigens to
the patient’s immune system (ie, polyvalent). For
autologous vaccines, tumor cells are isolated from
the patient, irradiated, combined with an immunos-
timulatory agent, and then infused or injected back
into the same patient. However, this technique
requires sufficient tumor specimen and is, thus,
limited to certain tumor types, and has cost and
feasibility barriers. Allogeneic vaccines may over-
come some of the limitations of autologous vaccines
because they are derived from established tumor
cell lines and can be produced on a large scale. The
Table 1. Therapeutic Cancer Vaccines in Clinical Development
Vaccine
Class Vaccine Name Description
Clinical Development Status by Tumor Type
Phase I Phase II Phase III Approved
Tumor cell Algenpantucel-L
(HyperAcute,
NewLink Genetics,
Ames, IA)
Allogeneic human
pancreatic cancer
vaccine based on
the concept of
hyperacute
rejection
RCC,
prostate
Melanoma,
NSCLC
Pancreatic –
Pancreatic tumor
cell vaccine (GVAX,
Aduro Biotech,
Berkeley, CA)
GM-CSF gene-
transfected tumor
cell vaccine
MM,
melanoma
Pancreatic,
AML, CML
– –
SL-701 Multivalent glioma-
associated antigen
vaccine
– GBM – –
DC/APCs Sipuleucel-T
(Provenge
Dendreon Corp,
Seattle, WA)
Autologous PBMCs
activated with PAP-
GM-CSF
– – – Prostate
AGS-003 Autologous DCs trans-
fected with tumor
and CD40L RNAs
– – RCC –
DCVAC/Pca Autologous DCs pulsed
with killed prostate
cancer line LNCap
– Prostate Prostate –
DCVax-L
(Northwest
Biotherapeutics,
Bethesda, MD)
Autologous DCs
pulsed with tumor
lysate antigen
– – GBM –
CVac (Prima
BioMed, Sydney,
Australia)
Autologous DCs
pulsed with MUC1-
mannan fusion
protein
– Ovarian – –
GRNVAC1 Autologous DCs
transfected with
hTERT and LAMP-1
– AML – –
ICT-107 Autologous DCs
pulsed with
antigens
– GBM – –
Ovapuldencel-T Autologous PBMCs in
GM-CSF
– Ovarian,
peritoneal
– –
MelCancerVac
(DanDrit Biotech,
Randolph, VT)
Autologous DCs pulsed
with allogeneic
melanoma cell
lysate
– CRC,
NSCLC
– –
DCP-001 Allogeneic dendritic
progenitor cells
(DCOne™)
– AML – –
BPX-201 Autologous DCs
engineered with
the DeCIDe
technology to
target prostate
cancer cells
Prostate – – –
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Table 1 (continued )
Vaccine
Class Vaccine Name Description
Clinical Development Status by Tumor Type
Phase I Phase II Phase III Approved
Peptides/
proteins
GV1001 hTERT peptide Melanoma,
pancreatic
HCC NSCLC,
pancreatic
–
Nelipepimut-S
(NeuVax, Galena
Biopharma, Inc,
Portland, OR)
HER2/neu peptide
combined with
GM-CSF
– – Breast –
L-BLP25
(Tecemotide)
Liposome-
encapsulated
synthetic peptide
derived from
MUC-1
– Rectal,
NSCLC,
MM,
prostate,
CRC
NSCLC –
Rindopepimut hEGFR variant III
speciﬁc peptide
conjugated to KLH
– GBM GBM –
POL-103A Protein antigens from
3 melanoma cell
lines with alum
adjuvant
– – Melanoma –
IMA901 Synthetic vaccine
consisting of 10
different TUMAPs
– – RCC –
MAGE-A3 MAGE-A3 combined
with GM-CSF
MM Bladder Melanoma –
PVX-410 Multi-peptide vaccine MM – – –
IMA950 Multi-peptide glioma
vaccine containing
TUMAPs
GBM GBM – –
Genetic Rilimogene
galvacirepvec
(PROSTVAC,
Bavarian Nordic,
Kvistgaard,
Denmark)
Recombinant
fowlpox/vaccinia
virus encoding
hPSA and TRICOM
Prostate Prostate Prostate –
CG0070 Oncolytic adenovirus
encoding GM-CSF
– Bladder – –
TG4010 Modiﬁed vaccinia
virus encoding
human MUC1 and
IL-2
Solid
tumors
NSCLC – –
Abbreviations: AML, acute myeloid leukemia; APC, antigen-presenting cell; CML, chronic myelogenous leukemia; CRC, colorectal
cancer; DC, dendritic cell; EGFR, epidermal growth factor receptor; GBM, glioblastoma; GM-CSF, granulocyte-macrophage colony-
stimulating factor; HCC, hepatocellular carcinoma; hPSA, human prostate speciﬁc antigen; hTERT, human telomerase reverse
transcriptase; IL-2, interleukin-2; KLH, keyhole limpet hemocyanin; MM, multiple myeloma; MUC1, mucin 1; NSCLC, non-small-cell
lung cancer; PBMC, peripheral blood mononuclear cells; RCC, renal cell carcinoma; TRICOM, recombinant vaccinia virus vaccine
encoding 3 co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3; TUMAPs, tumor-associated peptides.
Note: This is not a complete list of all therapeutic cancer vaccines in clinical development.
Source: ClinicalTrials.gov.
M.L. DisisS6classic example of a polyvalent, allogeneic cancer
vaccine is CancerVax (CancerVax, Delaware), the
whole-melanoma cell vaccine for advanced mela-
noma.25 However, this vaccine was never shown to
improve OS, and development was halted.26 A morerecent example that is currently in late-stage devel-
opment is TRICOM, a combination of 3 immuno-
stimulants (B7.1, ICAM-1, and LFA-3) with
algenpantucel-L (HyperAcute, New Link, Ames,
Iowa), a whole-cell vaccine containing irradiated
Mechanism of action of immunotherapy S7pancreatic tumor cells modified to express alpha
1,3-galactosyltransferase.
A variety of DC-based vaccines are also in develop-
ment (Table 1). Dendritic cells are the most potent
APCs and serve to bridge the gap between innate
and adaptive immunity.27 The main role of DCs is to
uptake, process, and present pathogen-derived or
host-derived antigenic peptides to naı¨ve T cells in
peripheral tissues.28,29 Numerous studies have eval-
uated vaccines containing peptide-pulsed or protein-
pulsed, or viral-vector infected DCs in a variety of
tumor types.30,31 Sipuleucel-T, which consists of
APCs from peripheral blood mononuclear cells
that have been incubated with prostatic acid phos-
phatase (PAP) fused to GM-CSF, was the first
FDA-approved autologous cell vaccine and is indi-
cated for men with metastatic castration-resistant
prostate cancer.32,33
Protein/peptide-based cancer vaccines are gener-
ally derived from specific TAAs and are typically
administered with an adjuvant or immune modulator
to enhance the immune response to that peptide.24
Investigators at the National Cancer Institute pio-
neered the identification and cloning of tumor-
associated peptide antigens recognized by TILs
isolated from patients.34 A potential disadvantage of
this approach is that protein/peptide-based vaccines
target only one or a few epitopes of the TAA, and
peptide antigens are not processed and presented by
APCs in the same way that antigens from whole cells
are. Therefore, they may not stimulate an effective
T-cell–mediated immune response. It is generally
thought that cancer vaccines must induce both
antigen-specific CD4þ helper T cells and CD8þ
cytotoxic T lymphocytes (CTLs) to be effective.
Nevertheless, several protein/peptide-based vaccines
are currently in clinical development. For example,
DPX-0907, which was created from human leuko-
cyte antigen (HLA)-A2 restricted peptides, has
yielded encouraging results in an early trial in
patients with advanced-stage breast, ovarian, or
prostate cancers.35 An epidermal growth factor
(EGF)-based protein vaccine is also being investi-
gated in patients with advanced non-small-cell lung
cancer.36 Additional peptide-based approaches using
longer epitopes that will elicit both CD4 and CD8
T cells in a non–HLA-restricted fashion are currently
under clinical development.
Genetic vaccines (DNA-based, RNA-based, and
viral-based) can be used to induce somatic cells or
DCs to express TAAs, thus resulting in cross-priming
or direct antigen presentation (Table 1).24 An impor-
tant advantage of genetic vaccines is the ability to
deliver multiple antigens in a single immunization,
resulting in the activation of different types of
immunity.37 Initially, DNA vaccines showed promise
in preclinical studies; however, clinical results havebeen disappointing.38–40 Novel constructs and meth-
ods of administration are currently in development
and may improve the effectiveness of DNA vaccines.
Unlike DNA vaccines, RNA vaccines are rapidly
degraded and cleared, and thus are less likely to
cause side effects.24 Early phase I/II trials of RNA
vaccines have been conducted in patients with
melanoma and renal cell carcinoma (RCC).41–48 Viral
vectors with low disease-causing potential and low
intrinsic immunogenicity, such as poxvirus, adeno-
virus, and Herpes simplex virus type 1, have been
evaluated in late-stage clinical trials.24ADOPTIVE T-CELL THERAPY
Adoptive T-cell therapy involves infusion of
ex vivo activated and expanded tumor-specific
T cells into the patient.49 Various sources and types
of T cells have been used for adoptive therapy,
including TILs, engineered T cells that express a
cancer-specific T-cell receptor (TCR), and engineered
T cells that express a chimeric antigen receptor
(CAR). Each of these approaches has its own advan-
tages and disadvantages.
It has long been known that human T cells
isolated from peripheral blood, tumor-draining
lymph nodes, or tumor tissue have selective anti-
tumor activity, and this provided the rationale for
using TILs for cancer immunotherapy more than
20 years ago.50,51 Early studies demonstrated the
feasibility of this approach for treating melanoma
and RCC.50 Although TILs provide an individualized
approach to immunotherapy, isolating and expand-
ing TILs ex vivo can be cumbersome and costly.
Additionally, to maximize their anti-tumor activity
following adoptive transfer, many investigators co-
administered high-dose IL-2, which can cause signifi-
cant toxicity.49 Results from several studies have
shown impressive clinical responses in patients with
metastatic melanoma treated with TILs,52–54 and
responses can be enhanced further by lymphodeple-
tion prior to reinfusion of TILs.53–54 Presumably,
agents that drastically reduce lymphocytes also
deplete Tregs that can suppress the activity of TILs.
Studies are ongoing to identify more efficient and
safer methods to culture and administer TILs and to
overcome tumor-induced immunosuppression.
Another approach to adoptive T-cell therapy is the
use of genetically engineered TCRs. Genes encoding
TCRs with specificity for TAAs in the context of
common HLA alleles are transduced into CD4þ and
CD8þ peripheral blood lymphocytes, thus generat-
ing tumor-specific T cells.51 Any patient whose
tumor expresses the correct HLA allele and the
target antigen recognized by the TCR could poten-
tially benefit from this therapy. Although initial
studies have demonstrated some clinical benefit of
M.L. DisisS8TCRs in patients with metastatic melanoma, the
treatment has been associated with significant tox-
icity to normal tissues that also express the target
antigen.55 Advancing this approach will require the
identification of more tumor-specific target antigens.
T cells also can be engineered to express a CAR,
which combines the extracellular portion of an anti-
body with the signaling capabilities of the TCR, thus
expanding the spectrum of tumor antigen recogni-
tion.56 Several generations of CARs have been devel-
oped. Despite encouraging early clinical results with
second-generation CARs in patients with lymphoma,
this approach also has been associated with signifi-
cant toxicity.57–61 Current studies are aimed at reduc-
ing toxicity while maintaining efficacy.IMMUNE CHECKPOINT INHIBITORS
Numerous inhibitory pathways are built into the
immune system to maintain self-tolerance and homeo-
stasis, and these are collectively referred to as
immune checkpoints.62 The primary role of immune
checkpoints is to protect tissues from damage when
the immune system is responding to pathogens and to
maintain tolerance to self-antigens (ie, prevent auto-
immunity). This is primarily achieved by down-
regulating T-cell activation or effector functions. A
growing body of evidence demonstrates that a pri-
mary mechanism by which tumors evade the immune
system is by engaging immune checkpoints. This has
spurred the development of many novel agents that
modulate immune checkpoints or other co-
stimulatory receptors (Table 2).
The first checkpoint receptor to be successfully
targeted as an immunotherapy is CTLA-4.63 It is
expressed on activated T cells, and its primary
function is to down-regulate the extent of T-cell
activation by countering the co-stimulatory signal
delivered by CD28.64–66 Both CTLA-4 and CD28
share the same ligands, CD80 (also known as B7.1)
and CD86 (also known as B7.2); however, CTLA-4
has a higher affinity for these ligands and thus out-
competes CD28 for ligand binding, thereby damp-
ening and limiting the T-cell response.67–70 The
critical role of CTLA-4 in keeping T-cell activation
in check is demonstrated by the lethal systemic
immune hyperactivation phenotype of CTLA-4-
knockout mice.71,72 Ipilimumab, an anti-CTLA-4
monoclonal antibody, was the first immune check-
point inhibitor to receive FDA approval for the
treatment of advanced melanoma.73 Tremelimumab,
another anti-CTLA-4 monoclonal antibody, is in
phase II development for mesothelioma and a variety
of other solid tumors. These antibodies bind to
CTLA-4 and block its immune-suppressive signal. As
a result, activated T cells, including those activated
by tumor antigens can continue to proliferate,produce cytokines, and exert their cytotoxic effector
functions in the tumor microenvironment. Unfortu-
nately, this can sometimes lead to undesired
immune-related adverse events caused by an auto-
immune reaction to normal tissues.
Targeting PD-1, another immune checkpoint
receptor, and its ligands, programmed cell death
ligand 1 (PD-L1) and PD-L2, is also emerging as a
promising immunotherapeutic modality.63 Similar to
CTLA-4, PD-1 plays a key role in regulating and
maintaining the balance between T-cell activation
and immune tolerance.74,75 Unlike CTLA-4, however,
PD-1 is broadly expressed and can be found, in
addition to T cells, on B cells and NK cells.76,77
While CTLA-4 primarily regulates T-cell activation in
the lymphatic tissues, the main role of PD-1 is to
limit T-cell activity in peripheral tissues during a cell-
mediated or inflammatory immune response.74,75,78–82
Tumors can exploit this checkpoint and render TILs,
particularly CTLs and NK cells, anergic and unable to
kill. The ligand PD-L1 is commonly upregulated on
several human solid tumors including melanoma,
lung, and ovarian tumors.83,84 Mice lacking the Pdl,
Pdl1, and Pdl2 genes have a milder autoimmune
phenotype than CTLA-4-knockout mice.80,81,85,86
Several monoclonal antibodies targeting PD-1 (nivo-
lumab [BMS-936558], pidilizumab [CT-011], and
lambrolizumab [MK-3475]) and PD-L1 (BMS-
936559, MPDL3280A, MSB0010718C, and
MEDI4736) are in various stages of clinical develop-
ment (Table 2). An anti-PD-1 fusion protein, AMP-
224, is also in early clinical development. Although
no agents targeting PD-1 or its ligands have gained
FDA approval yet, clinical studies to date have
yielded encouraging results with significant durable
response rates in several tumor types, particularly
melanoma, RCC, and lung cancer.
Another regulator of the immune response that
functions in the tumor microenvironment is the IDO
pathway. IDO normally functions to prevent damage
from excessive immune activation by breaking down
tryptophan, which is required for T-cell activity.87
Tumor cells often exploit this pathway by over-
expressing IDO in the presence of effector cell
stimuli. Thus, IDO inhibitors have the potential to
alter the tumor microenvironment and boost the
T-cell–mediated immune response.CO-STIMULATORY RECEPTORS
In contrast to the B7/CTLA-4 and PD-L1/PD-1
interactions that suppress T-cell activation, several
co-stimulatory receptors are being explored as ther-
apeutic targets. Agents capable of activating co-
stimulatory receptors such as OX40 and 4-1BB have
entered clinical development recently (Table 2).
Preclinical research indicates that these agents may
Table 2. Immune Checkpoint Modulators in Clinical Development
Target Drug Name
Clinical Development Status by Tumor Type
Phase I Phase II Phase III Approved
Check-
point
Inhibitors
CTLA-4 Ipilimumab
(Yervoy, Bristol-
Myers Squibb Co,
Princeton, NJ))
Pancreatic Gastric,
ovarian
NSCLC,
SCLC,
prostate
Melanoma
Tremelimumab – Mesothe-
lioma, solid
tumors
– –
PD-1 MK-3475
(lambrolizumab)
Solid tumors,
MM, hematologic
RCC, CRC NSCLC,
melanoma
–
Nivolumab (BMS-
936558)
HCC, CRC,
prostate,
hematologic
Brain, NHL,
esophageal,
solid tumors
Melanoma,
NSCLC,
RCC
–
Pidilizumab (CT-
011)
– Melanoma,
DLBCL-NHL,
AML, iNHL
– –
MEDI0680 (AMP-
514)
Solid tumors – – –
PD-L1 MEDI4736 – Melanoma,
solid tumors
NSCLC –
RG7446
(MPDL3280A)
Melanoma, solid
tumors
RCC,
bladder
NSCLC –
BMS-936559 Solid tumors – – –
MSB0010718C Solid tumors – – –
PD-L2 AMP-224 Solid tumors – – –
KIR Lirilumab (BMS-
986015)
Solid tumors AML – –
IDO Indoximod Pancreatic,
melanoma, brain
Breast,
prostate
– –
Co-
stimula-
tory
proteins
OX40 Anti-OX40 – Prostate – –
4-1BB
(CD137)
Urelumab (BMS-
663513)
B-cell
malignancies,
solid tumors
Melanoma – –
Other
proteins
LAG-3
(CD223)
BMS-986016 Solid tumors, CLL,
HL, NHL
– – –
Phosphati-
dylserine
Bavituximab Rectal, breast,
liver, melanoma
Pancreatic,
breast,
NSCLC,
– –
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CRC, colorectal cancer; CTLA-4, cytotoxic
T-lymphocyte-associated antigen 4; DLBCL, diffuse large B-cell lymphoma; HCC, hepatocellular carcinoma; HL, Hodgkin lymphoma;
IDO, indoleamine-2,3-dioxygenase; iNHL, indolent non-Hodgkin lymphoma; KIR, killer cell immunoglobulin—like receptor; LAG-3,
lymphocyte-activation gene 3; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; NSCLC, non-small-cell lung cancer; PD-1,
programmed cell death 1; PD-L1, programmed cell death ligand 1; PD-L2, programmed cell death ligand 2; RCC, renal cell carcinoma;
SCLC, small-cell lung cancer.
Note: This is not a complete list of immune checkpoint modulators in clinical development.
Source: ClinicalTrials.gov.
Mechanism of action of immunotherapy S9be most beneficial when given in combination with
immune checkpoint inhibitors.50,88,89 OX40 is a
member of the TNF receptor superfamily and is
predominantly expressed on CD4þ and CD8þ T
cells.89 Preclinical studies in immunogenic tumor
models have demonstrated that an agonist monoclo-
nal antibody to OX40 enhances anti-tumorimmunity, and results from a recent phase I trial
were encouraging.90 Agonist monoclonal antibodies
against 4-IBB, another member of the TNF receptor
superfamily, also have shown promising anti-tumor
effects in preclinical studies; however, these agents
have not yet entered clinical development.88 Indu-
cible co-stimulator (ICOS) is another T cell-specific
M.L. DisisS10co-stimulatory molecule that is a member of the
CD28/CTLA-4 family.91,92 T-cell activation results in
upregulation of ICOS, and this upregulation is fur-
ther enhanced upon CTLA-4 blockade.93,94 A recent
study demonstrated that concomitant ICOS stimula-
tion and CTLA-4 inhibition enhanced anti-tumor
responses in preclinical mouse models of melanoma
and prostate cancer, thus supporting the potential of
this combination approach.95 Likewise, agonists of
TLRs regulate the activity of APCs and can have both
immune stimulatory or immune inhibitory effects
depending on whether they induce expression of co-
stimulatory molecules (eg, CD80, CD86, and CD40)
and proinflammatory cytokines (eg, TNF-α and IL-12)
or instead induce expression of co-inhibitory mole-
cules (eg, IL-10 and PD-L1).96 Studies have demon-
strated that concomitant blockade of IL-10 or PD-L1
can augment the anti-tumor effects of TLR agonists.CONCLUSIONS
Cancer immunotherapy has been studied and
tested for several decades, but only recently have
immune-based therapies been shown to provide an
OS benefit in patients with advanced cancer. For
many years, success was limited to a select few
patients. As our understanding of the complex
interactions between tumors and the immune sys-
tem has advanced, a range of new therapeutic
strategies has been developed. These new agents
exploit a wide array of mechanisms to enhance the
anti-tumor immune response and are beginning to
have a clinical impact on the treatment of many
different tumor types. Clinical results of approved
and emerging immunotherapies will be discussed
further in the articles by Weber and Rini within this
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